Adaptimmune Therapeutics (ADAP.Y) Panoramica del titolo
Adaptimmune Therapeutics plc, un'azienda biofarmaceutica in fase commerciale, fornisce nuove terapie cellulari principalmente a pazienti affetti da cancro negli Stati Uniti e nel Regno Unito. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 0/6 |
| Dividendi | 0/6 |
ADAP.Y Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Adaptimmune Therapeutics plc
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$0.018 |
| Massimo di 52 settimane | US$0.36 |
| Minimo di 52 settimane | US$0.0001 |
| Beta | 1.89 |
| Variazione di 1 mese | 16.67% |
| Variazione a 3 mesi | 59.09% |
| Variazione di 1 anno | -93.62% |
| Variazione a 3 anni | -98.50% |
| Variazione a 5 anni | -99.65% |
| Variazione dall'IPO | -99.90% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Feb 11
ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential
Analysts have adjusted their price target on Adaptimmune Therapeutics to $1.50, keeping it aligned with their fair value estimate as they factor in an updated discount rate of 13.43%, steady high revenue growth assumptions near 46.25%, a slightly lower projected profit margin close to 16.05%, and a marginally higher future P/E expectation near 19.36. What's in the News Adaptimmune Therapeutics plans executive changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of Adrian Rawcliffe in connection with a company restructuring (Key Developments).Aggiornamento della narrazione • Jan 26
ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential
Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).Aggiornamento della narrazione • Jan 12
ADAP.Y: Leadership Transition And Deregistration Will Shape Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have kept their price target for Adaptimmune Therapeutics broadly steady at around $1.50 per share. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior estimates.Aggiornamento della narrazione • Dec 16
ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models. What's in the News Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).Aggiornamento della narrazione • Dec 02
ADAP.Y: Leadership Transition And Deregistration Will Drive Further Upside Potential
Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.Recent updates
Aggiornamento della narrazione • Feb 11
ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential
Analysts have adjusted their price target on Adaptimmune Therapeutics to $1.50, keeping it aligned with their fair value estimate as they factor in an updated discount rate of 13.43%, steady high revenue growth assumptions near 46.25%, a slightly lower projected profit margin close to 16.05%, and a marginally higher future P/E expectation near 19.36. What's in the News Adaptimmune Therapeutics plans executive changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of Adrian Rawcliffe in connection with a company restructuring (Key Developments).Aggiornamento della narrazione • Jan 26
ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential
Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).Aggiornamento della narrazione • Jan 12
ADAP.Y: Leadership Transition And Deregistration Will Shape Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have kept their price target for Adaptimmune Therapeutics broadly steady at around $1.50 per share. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior estimates.Aggiornamento della narrazione • Dec 16
ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models. What's in the News Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).Aggiornamento della narrazione • Dec 02
ADAP.Y: Leadership Transition And Deregistration Will Drive Further Upside Potential
Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.Aggiornamento della narrazione • Nov 18
ADAP.Y: Voluntary SEC Deregistration and Index Removals Will Unlock Future Value
Analysts have raised their price target for Adaptimmune Therapeutics from $0.98 to $1.50. This change reflects updated expectations for valuation and revised future earnings metrics.Aggiornamento della narrazione • Nov 03
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
Analysts have raised the price target for Adaptimmune Therapeutics from $0.64 to $0.98 per share. This change reflects increased optimism on future revenue growth and profit margins, despite a slightly higher discount rate.Aggiornamento della narrazione • Aug 22
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Analysts have lowered their price target for Adaptimmune Therapeutics, citing solvency concerns, ongoing strategic uncertainty, and a lack of near-term catalysts, resulting in a revised fair value from $0.714 to $0.638. Analyst Commentary Bearish analysts cite significant solvency and sustainability concerns, questioning whether the company has sufficient financial resources to navigate near-term challenges.Aggiornamento della narrazione • Aug 07
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Despite a modestly improved revenue growth outlook and a significantly lower forward P/E, consensus analyst sentiment has worsened, leading to a marked price target reduction from $0.96 to $0.714. What's in the News Adaptimmune Therapeutics reached a settlement with MD Anderson Cancer Center to resolve litigation related to a previous strategic alliance, with all claims to be dismissed upon payment.
Nuova narrazione • Apr 04
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.Articolo di analisi • Mar 11
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders that were waiting for something to happen have been dealt a...Articolo di analisi • Jan 01
Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%
To the annoyance of some shareholders, Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares are down a considerable 26...Articolo di analisi • Dec 15
Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Unfortunately for some shareholders, the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) share price has dived 32% in the...Articolo di analisi • Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders won't be pleased to see that the share price has had a very...Seeking Alpha • Sep 12
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Summary Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma and a boxed warning for cytokine release syndrome. The U.S. population eligible for Tecelra is small, approximately 100-400 patients, based on various eligibility factors. The collaboration with Galapagos provides $70 million upfront and potential milestone payments up to $465 million, expanding the development of uza-cel in solid tumors. Adaptimmune’s Q2 2024 revenue jumped due to deferred revenue from the terminated Genentech collaboration, resulting in a $69.5 million net profit. Given the limited market and logistical complexities, the likelihood of peak revenue exceeding $200 million is low, presenting high investment risk. Read the full article on Seeking AlphaSeeking Alpha • Jul 03
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Summary Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further. Read the full article on Seeking AlphaSeeking Alpha • Apr 26
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Summary Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon. Read the full article on Seeking AlphaArticolo di analisi • Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have retraced a considerable 29% in the last month, reversing a...Articolo di analisi • Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have continued their recent momentum with a 107% gain in the last...Seeking Alpha • Feb 02
Adaptimmune: Drug Approval Now Imminent?
Summary Adaptimmune's BLA for their T-cell therapy in soft tissue sarcomas has been accepted for review by the FDA. The company's lead candidate, Afami-cel, has shown promising results in synovial sarcoma, with a PDUFA date set for August 4, 2024. Adaptimmune's cash position is low, but expected milestone payments from their collaboration with Genentech may extend their cash runway. Read the full article on Seeking AlphaArticolo di analisi • Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders are no doubt pleased to see that the share price has bounced...Articolo di analisi • Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...Articolo di analisi • Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Shareholders in Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) may be thrilled to learn that the analysts have just...Articolo di analisi • Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 20
Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Summary Adaptimmune Therapeutics plans to file a BLA this year. Despite that, the stock remains depressed. Their cash position is difficult as well.Articolo di analisi • Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Rendimenti per gli azionisti
| ADAP.Y | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -12.5% | -1.6% | -0.8% |
| 1Y | -93.6% | 34.4% | 27.1% |
Ritorno vs Industria: ADAP.Y ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 34.4 % nell'ultimo anno.
Rendimento vs Mercato: ADAP.Y ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.1 % nell'ultimo anno.
Volatilità dei prezzi
| ADAP.Y volatility | |
|---|---|
| ADAP.Y Average Weekly Movement | 2,808.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di ADAP.Y è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di ADAP.Y è aumentata da 1413% a 2809% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2008 | 506 | Chris Hill | www.adaptimmune.com |
Adaptimmune Therapeutics plc, un'azienda biofarmaceutica in fase commerciale, fornisce nuove terapie cellulari principalmente a pazienti oncologici negli Stati Uniti e nel Regno Unito. Sviluppa TECELRA ((famitresgene autoleucel o afami-cel), un'immunoterapia a cellule T autologhe geneticamente modificate per il trattamento di adulti con sarcoma sinoviale non resecabile o metastatico; Lete-cel per il trattamento del sarcoma sinoviale e del liposarcoma mixoide; e ADP-5701, in fase di sperimentazione clinica di Fase 1 per il trattamento del tumore della testa e del collo. L'azienda si concentra anche sullo sviluppo di terapie a base di cellule T dirette a PRAME (ADP-600) e CD70 (ADP-520).
Adaptimmune Therapeutics plc Riepilogo dei fondamenti
| ADAP.Y statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$3.98m |
| Utili (TTM) | -US$169.76m |
| Ricavi(TTM) | US$65.09m |
0.1x
Rapporto P/S0.0x
Rapporto P/EADAP.Y è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ADAP.Y Conto economico (TTM) | |
|---|---|
| Ricavi | US$65.09m |
| Costo del fatturato | US$128.69m |
| Profitto lordo | -US$63.61m |
| Altre spese | US$106.15m |
| Utili | -US$169.76m |
Ultimi utili riportati
Jun 30, 2025
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.64 |
| Margine lordo | -97.73% |
| Margine di profitto netto | -260.82% |
| Rapporto debito/patrimonio netto | -36.2% |
Come si è comportato ADAP.Y nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 18:19 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2025/06/30 |
| Utili annuali | 2024/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Adaptimmune Therapeutics plc è coperta da 8 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ying Huang | BofA Global Research |
| Mohit Bansal | Citigroup Inc |
| Reni Benjamin | Raymond James & Associates |